MECHANISM OF RESISTANCE TO CARBAPENEM IN CLINICAL ISOLATES OF BACTEROIDES-FRAGILIS

被引:3
|
作者
PODGLAJEN, I
BREUIL, J
RUIMY, R
BOURGAULT, AM
BETRIU, C
CASIN, I
CHRISTEN, R
COLLATZ, E
机构
[1] Laboratoire de Recherche Medicale sur les Mecanismes Moleculaires de l'Activite des Antibiotiques, Université Paris VI, F-75006 Paris
[2] Hôpital Intercommunal, F-94195 Villeneuve-Saint-Georges cedex, 40, Allée de la Source
[3] CNRS-URA 617 et Université Paris VI
[4] Hôpital Saint-Luc, Montréal
[5] Hôpital San Carlos, Madrid
[6] Hôpital Saint-Louis, F-75475 Paris cedex 10, I avenue Claude Vellefaux
来源
关键词
BACTEROIDES-FRAGILIS; CFIA; RESISTANCE GENE ACTIVATION; IS1186;
D O I
10.1016/S0399-077X(05)81274-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Carbapenem (imipenem [IMI], meropenem [MER]) resistance in clinical isolates of Bacteroides fragilis is due to the production of a carbapenemase, a Zn++-dependent metallo beta-lactamase, encoded by the gene cfiA. This gene is carried by ca. 3 % of the B. fragilis strains isolated in France, but is expressed (MICs of IMI, MER greater-than-or-equal-to 64 mug/ml) in only one third of the cases, and silent (MICs of IMI/MER = 1/2 mug/ml) in the remaining two thirds. Activation of the silent gene occurs, in vitro and in vivo, after insertion of an IS element, most frequently IS1186, carrying a strong promoter, immediately upstream of the gene. The cfiA-positive strains differ from the cfiA-negative strains in that they harbor the IS elements known in B. fragilis (IS4351, IS1186, IS942) and they constitute, on the basis of molecular typing and sequencing of 16S RNA genes, a distinct taxonomical unit.
引用
收藏
页码:590 / 593
页数:4
相关论文
共 50 条
  • [11] PLASMID ANALYSIS OF CLINICAL ISOLATES OF BACTEROIDES-FRAGILIS GROUP STRAINS
    NAGY, E
    DANYI, E
    FOLDES, J
    ACTA MICROBIOLOGICA HUNGARICA, 1990, 37 (04): : 367 - 373
  • [12] MECHANISM OF ACTION OF METRONIDAZOLE ON BACTEROIDES-FRAGILIS
    SIGETI, JS
    GUINEY, DG
    DAVIS, CE
    JOURNAL OF INFECTIOUS DISEASES, 1983, 148 (06): : 1083 - 1089
  • [13] BACTEROIDES-FRAGILIS RESISTANCE TO CLINDAMYCIN INVITRO
    SOSA, A
    TALLY, FP
    JACOBUS, NV
    GORBACH, SL
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 22 (05) : 771 - 774
  • [14] RIFAMPIN AND BACTERIOCIN RESISTANCE IN BACTEROIDES-FRAGILIS
    MOSSIE, KG
    JONES, DT
    ROBB, FT
    WOODS, DR
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 17 (05) : 838 - 841
  • [15] ANTIGENIC CHARACTERISTICS OF ENTEROTOXIGENIC AND NONENTEROTOXIGENIC ISOLATES OF BACTEROIDES-FRAGILIS
    MYERS, LL
    SHOOP, DS
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 1987, 48 (04) : 643 - 645
  • [16] SUSCEPTIBILITY PATTERNS AND CHARACTERIZATION OF BETA-LACTAMASES IN CLINICAL ISOLATES OF BACTEROIDES-FRAGILIS
    MASTRANTONIO, P
    SPIGAGLIA, P
    SEBASTIANELLI, A
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (06) : 475 - 480
  • [17] INCREASED RESISTANCE OF ENCAPSULATED BACTEROIDES-FRAGILIS TO CLINDAMYCIN
    BROOK, I
    GILLMORE, JD
    CHEMOTHERAPY, 1994, 40 (01) : 16 - 20
  • [18] CONJUGAL TRANSFER OF IMIPENEM RESISTANCE IN BACTEROIDES-FRAGILIS
    BANDOH, K
    WATANABE, K
    MUTO, Y
    TANAKA, Y
    KATO, N
    UENO, K
    JOURNAL OF ANTIBIOTICS, 1992, 45 (04): : 542 - 547
  • [19] ISOLATION AND CHARACTERIZATION OF SEVERAL CRYPTIC PLASMIDS FROM CLINICAL ISOLATES OF BACTEROIDES-FRAGILIS
    STIFFLER, PW
    KELLER, R
    TRAUB, N
    JOURNAL OF INFECTIOUS DISEASES, 1974, 130 (05): : 544 - 548
  • [20] EPIDEMIOLOGY OF CLINDAMYCIN RESISTANCE IN THE BACTEROIDES-FRAGILIS GROUP
    REIG, M
    CAMPELLO, MG
    BAQUERO, F
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1984, 14 (06) : 595 - 603